Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

71.25 +0.41 (+0.57%)
Streaming Delayed Price Updated: 1:55 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
42 43 Next >
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
Via Benzinga
AstraZeneca's COVID-19 Antibody Shows 83% Protection Over Six Months
AstraZeneca Plc (NASDAQ: AZN) has shared new data from two Phase 3 trials of AZD7442, its long-acting antibody (LAAB) combination, in COVID-19 patients. In an... 
Via Benzinga
Exposures COVID-19
Tuesday Market Overview
While gold gained modestly again today, cryptocurrencies fell hard. 
Via Talk Markets
Monday Market Coverage
Gold is up today on inflation fears. 
Via Talk Markets
AstraZeneca: Expected To Move Upwards
Today’s instrument is the Astrazeneca Plc. stock traded in the LSE exchange under the ticker AZN. 
Via Talk Markets
AstraZeneca, Moderna Shares Early Cut Data For mRNA Candidate In Heart Failure
Moderna Inc (NASDAQ: MRNA) announced data from the AstraZeneca Plc (NASDAQ: AZN)-led Phase 2 (EPICCURE) study evaluating AZD8601 in patients undergoing... 
Via Benzinga
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of... 
Via Benzinga
Consumer Sentiment Hit a Decade Low Due to Rising Inflation
Stock index futures are pointing to a higher open as President Joe Biden is expected to sign the infrastructure bill. Additionally, President Biden is scheduled to meet with... 
Via Benzinga
Moderna Posts Interim Data From mRNA Triplet Program In Solid Tumors
Moderna Inc (NASDAQ: MRNA) announced interim data from Phase 1 study of mRNA-2752 (Triplet) in patients with accessible solid tumors and lymphomas. The data... 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges 150 Points; Team Shares Drop
Toward the end of trading Friday, the Dow traded up 0.42% to 36,071.48 while the NASDAQ rose 0.84% to 15,835.89. The S&P also rose, gaining 0.61% to 4,677.60. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why AstraZeneca Stock Is Sinking Today
The drugmaker announced disappointing third-quarter earnings results. 
Via The Motley Fool
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
Mid-Day Market Update: Everspin Jumps After Q3 Results; Acutus Medical Shares Plummet
Midway through trading Friday, the Dow traded up 0.31% to 36,031.95 while the NASDAQ rose 0.54% to 15,788.64. The S&P also rose, gaining 0.43% to 4,669.15. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Morning Market Update: Markets Rise; AstraZeneca's COVID-19 Vaccine Turns Profitable In Third Quarter
Following the market opening Friday, the Dow traded up 0.25% to 36,012.29 while the NASDAQ rose 0.24% to 15,741.23. The S&P also rose, gaining 0.14% to 4,655.99. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures COVID-19 US Equities
Recap: AstraZeneca Q3 Earnings
AstraZeneca (NASDAQ:AZN) reported its Q3 earnings results on Friday, November 12, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance
AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine made a small contribution to earnings in Q3. It expects the shot to move to "modest profitability" on new... 
Via Benzinga
Exposures COVID-19
A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after closing mixed in the prior session. Investors are awaiting earnings results from... 
Via Benzinga
5 Stocks To Watch For November 12, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Spectrum Brands Holdings, Inc. (NYSE: SPB) to report quarterly earnings at $0.65 per share on... 
Via Benzinga
This Company's Innovative Targeted Radiation Therapy Could Offer Potential Hope for Cancer Patients
Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
Earnings Scheduled For November 12, 2021
Companies Reporting Before The Bell • Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million. • Natura &Co... 
Via Benzinga
Veteran's Day
Stock markets took a tumble today across the board, but not as far down as at the opening. 
Via Talk Markets
Valneva Shares Soar On Securing EU COVID-19 Vaccine Deal
Valneva SE (NASDAQ: VALN) shares jumped more than 20% after winning approval from the European Commission for a deal. Over two years, the Company would supply up... 
Via Benzinga
Exposures COVID-19
AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - Report
AstraZeneca plc (NASDAQ: AZN) is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
These Clinical Results Are Good News for AstraZeneca
AstraZeneca shared positive interim results for Imfinzi plus chemotherapy in treating patients with advanced biliary tract cancer. 
Via The Motley Fool
Moderna Is Melting - Why I Am Buying This Dip
Despite recent 
Via Talk Markets
Novavax Looks Primed and Ready for a Vaccine Comeback
NVAX stock looks enticing now after falling steeply due to delays in FDA emergency approval as well as other manufacturing issues. 
Via InvestorPlace
Exposures COVID-19 Product Safety
Ocugen Neared $16 Yesterday, But I’ll Eat 4 Hats If It Gets to $32
OCGN stock has moved higher despite little evidence anything’s changed regarding Ocugen’s revenue potential in the U.S. 
Via InvestorPlace
Exposures COVID-19
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The... 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.